Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00482

Submission Number:
00482
Commenter:
Ed Snell
State:
Idaho
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
"Why should any industry have a safe harbor for kickbacks? At a time when drug prices are soaring, and the public is at risk of harm from shortages of critical medications and sterile products, the FTC MUST investigate how the middlemen of GPO and PBM are causing these issues." "The PBM's practices are increasing healthcare costs to the patient and the payers (commercial and government). The discounts received due to their volume are being shared partially with the payers with the highest percent going to their bottom line." This CVS/Aetna merger should be denied to protect our healthcare system. Look at the data that shows this to be a bad merger. Believe it.